Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application of inhibitor of matrix metal metal protease (MMP) in use for treating hemorrhoid

A technology of protease inhibitors and matrix metals, applied in the field of matrix metalloproteinase inhibitors

Inactive Publication Date: 2005-08-31
BEIJING BIOSIS HEALING BIOLOGICAL TECH
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Matrix metalloproteinase (MMP) inhibitors and matrix metalloproteinase 9 (MMP9) inhibitors are currently mainly used in the treatment of cancer, ankylosing spondylitis, rheumatoid arthritis, gouty arthritis (gout), inflammatory arthritis, Lyme disease and osteoarthritis, so far, there is no literature report that matrix metalloproteinase (MMP) inhibitors are used for the treatment of hemorrhoids and for the preparation of medicines for the treatment of hemorrhoids

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of inhibitor of matrix metal metal protease (MMP) in use for treating hemorrhoid
  • New application of inhibitor of matrix metal metal protease (MMP) in use for treating hemorrhoid
  • New application of inhibitor of matrix metal metal protease (MMP) in use for treating hemorrhoid

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Embodiment 1: Elastic fiber and matrix metalloproteinase (MMP) expression situation and difference in hemorrhoid tissue and relatively normal anal cushion tissue

[0050] Selected 24 cases of suprahemorrhoidal mucosal circumcision and stapling (PPH surgery) specimens obtained from October 2003 to August 2004, mainly selecting one or two female hemorrhoids among the three female hemorrhoids with obvious lesions, but at least one female hemorrhoid Internal hemorrhoid specimens from patients with grade III hemorrhoids with inconspicuous "hemorrhoids" lesions. The patients were aged between 35-60. After PPH operation, the protruding female hemorrhoid tissue and relatively normal anal cushion tissue were fixed in 15% neutral formalin solution, embedded in paraffin, and serially sectioned.

[0051] Paraffin sections from all patients were stained by H.E. immunohistochemical streptavidin-biotin-peroxidase-linked (SP) method. Five kinds of monoclonal antibodies are respective...

Embodiment 2

[0062] Example 2: Preparation of suppository A containing matrix metalloproteinase inhibitor-COL-3

[0063] With conventional suppository preparation method, the following compounds are mixed in the content ratio described in the table (table 2):

[0064]

ingredient name

in each suppository

content of ingredients

Features

live

sex

become

Minute

COL-3

20mg

Matrix Metalloproteinase Inhibitors

That

he

become

Minute

Polyoxyethylene glycol palmitate

Fatty acid ester

160mg

Self-emulsifying fat base

Saturated Polysaccharide Glycerides

120mg

fat soluble carrier

Dimethicone

320mg

liquid solvent

Hydrophobic hydroxypropyl methylcellulose

white

275mg

retention matrix

Propylene Glycol

200mg

Potential solvent

Methylparaben

4mg

preservatives

Propylp...

Embodiment 3

[0067] Embodiment 3: the preparation of the suppository B containing matrix metalloproteinase inhibitor---rosiglitazone The following compound is mixed according to the content ratio described in the table (table 3) with conventional suppository preparation method:

[0068]

ingredient name

in each suppository

content of ingredients

Features

live

sex

become

Minute

Rosiglitazone

2mg

Matrix Metalloproteinase Inhibitors

That

he

become

Minute

Polyoxyethylene glycol palmitate

Fatty acid ester

160mg

Self-emulsifying fat base

Saturated Polysaccharide Glycerides

120mg

fat soluble carrier

Dimethicone

320mg

liquid solvent

Hydrophobic hydroxypropyl methylcellulose

white

275mg

retention matrix

Propylene Glycol

200mg

Potential solvent

Methylparaben

4mg

pre...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An application of the matrix metal proteinase (MMP) inhibitor, especially the inhibitor of 1(MMP1), 9 (MMP9) or 12 (MMP12), in preparing the medicines for preventing and / or treating piles is disclosed.

Description

Technical field: [0001] The present invention relates to a new application of matrix metalloproteinase (MMP) inhibitors, in particular to new applications of matrix metalloproteinase 1 (MMP1), matrix metalloproteinase 9 (MMP9) and matrix metalloproteinase 12 (MMP12) inhibitors. More specifically, the present invention relates to the use of matrix metalloproteinase (MMP) inhibitors, particularly matrix metalloproteinase 1 (MMP1), matrix metalloproteinase 9 (MMP9), matrix metalloproteinase 12 (MMP12) inhibitors to treat and / or prevent hemorrhoids . More specifically, the present invention relates to matrix metalloproteinase (MMP) inhibitors, especially matrix metalloproteinase 1 (MMP1), matrix metalloproteinase 9 (MMP9), matrix metalloproteinase 12 (MMP12) inhibitors in the preparation of treatment and / or prevention Use of a medicament or a pharmaceutical composition for hemorrhoids. Background of the invention: [0002] Hemorrhoids are the pathological changes and (or) abno...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/00A61K45/00A61P9/14
Inventor 王振军赵博韩炜
Owner BEIJING BIOSIS HEALING BIOLOGICAL TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com